JP2017006120A5 - - Google Patents

Download PDF

Info

Publication number
JP2017006120A5
JP2017006120A5 JP2016109398A JP2016109398A JP2017006120A5 JP 2017006120 A5 JP2017006120 A5 JP 2017006120A5 JP 2016109398 A JP2016109398 A JP 2016109398A JP 2016109398 A JP2016109398 A JP 2016109398A JP 2017006120 A5 JP2017006120 A5 JP 2017006120A5
Authority
JP
Japan
Prior art keywords
hla
molecule
drb1
cancer
peptide
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2016109398A
Other languages
English (en)
Japanese (ja)
Other versions
JP6298101B2 (ja
JP2017006120A (ja
Filing date
Publication date
Application filed filed Critical
Publication of JP2017006120A publication Critical patent/JP2017006120A/ja
Publication of JP2017006120A5 publication Critical patent/JP2017006120A5/ja
Application granted granted Critical
Publication of JP6298101B2 publication Critical patent/JP6298101B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2016109398A 2010-10-05 2016-05-31 ヘルパーt細胞の活性化方法 Active JP6298101B2 (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2010225806 2010-10-05
JP2010225806 2010-10-05

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
JP2012537718A Division JP6134139B2 (ja) 2010-10-05 2011-10-04 ヘルパーt細胞の活性化方法

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2017237964A Division JP2018093870A (ja) 2010-10-05 2017-12-12 ヘルパーt細胞の活性化方法

Publications (3)

Publication Number Publication Date
JP2017006120A JP2017006120A (ja) 2017-01-12
JP2017006120A5 true JP2017006120A5 (https=) 2017-05-25
JP6298101B2 JP6298101B2 (ja) 2018-03-20

Family

ID=45927725

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2012537718A Active JP6134139B2 (ja) 2010-10-05 2011-10-04 ヘルパーt細胞の活性化方法
JP2016109398A Active JP6298101B2 (ja) 2010-10-05 2016-05-31 ヘルパーt細胞の活性化方法
JP2017237964A Pending JP2018093870A (ja) 2010-10-05 2017-12-12 ヘルパーt細胞の活性化方法

Family Applications Before (1)

Application Number Title Priority Date Filing Date
JP2012537718A Active JP6134139B2 (ja) 2010-10-05 2011-10-04 ヘルパーt細胞の活性化方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2017237964A Pending JP2018093870A (ja) 2010-10-05 2017-12-12 ヘルパーt細胞の活性化方法

Country Status (21)

Country Link
US (2) US10654892B2 (https=)
EP (1) EP2626418B8 (https=)
JP (3) JP6134139B2 (https=)
KR (3) KR20140009168A (https=)
CN (2) CN105802910A (https=)
AR (1) AR083295A1 (https=)
AU (1) AU2011313327B2 (https=)
BR (1) BR112013008230A2 (https=)
CA (1) CA2813557C (https=)
CO (1) CO6710946A2 (https=)
EA (1) EA037547B1 (https=)
ES (1) ES2849187T3 (https=)
IL (2) IL225536B (https=)
MX (2) MX361299B (https=)
MY (1) MY170306A (https=)
NZ (2) NZ703560A (https=)
PH (1) PH12013500654A1 (https=)
SG (3) SG189287A1 (https=)
TW (2) TW201623616A (https=)
WO (1) WO2012046730A1 (https=)
ZA (1) ZA201303056B (https=)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101580538B (zh) 2003-11-05 2013-06-19 株式会社国际癌症免疫研究所 Wt1衍生的hla-dr-结合抗原肽
ES2542141T3 (es) 2005-10-17 2015-07-31 Sloan Kettering Institute For Cancer Research Péptidos WT1 de unión a HLA de clase II, y composiciones y métodos que los comprenden
PL2010209T3 (pl) 2006-04-10 2017-04-28 Sloan Kettering Inst For Cancer Res Immunogeniczne peptydy WT-1 i sposoby ich użycia
MX2009009168A (es) * 2007-02-27 2009-09-07 Int Inst Cancer Immunology Inc Metodo para activacion de celula t auxiliar y composicion para usarse en el metodo.
AR076349A1 (es) 2009-04-23 2011-06-01 Int Inst Cancer Immunology Inc Peptido auxiliar del antigeno del cancer
SG189287A1 (en) * 2010-10-05 2013-05-31 Int Inst Cancer Immunology Inc Method for activating helper t cell
CA2861206C (en) 2012-01-13 2021-07-06 Richard J. O'reilly Immunogenic wt-1 peptides and methods of use thereof
EP2896693A4 (en) * 2012-09-12 2016-10-12 Int Inst Cancer Immunology Inc ANTIGEN SPECIFIC HELPER T CELL RECEPTOR GENES
WO2014098012A1 (ja) * 2012-12-17 2014-06-26 大塚製薬株式会社 ヘルパーt細胞の活性化方法
EP3769782A1 (en) 2013-01-15 2021-01-27 Memorial Sloan Kettering Cancer Center Immunogenic wt-1 peptides and methods of use thereof
US10815273B2 (en) 2013-01-15 2020-10-27 Memorial Sloan Kettering Cancer Center Immunogenic WT-1 peptides and methods of use thereof
MY171854A (en) 2013-03-29 2019-11-05 Sumitomo Dainippon Pharma Co Ltd Wt1 antigen peptide conjugate vaccine
EP3112378B1 (en) * 2014-02-26 2020-06-24 Tella, Inc. Wt1 antigenic polypeptide, and anti-tumor agent containing said polypeptide
CA2974066C (en) 2014-12-25 2025-05-06 International Institute Of Cancer Immunology, Inc. METHOD FOR MODIFYING A T LYMPHOCYTE POPULATION
CN106565836B (zh) * 2015-10-10 2020-08-18 中国科学院广州生物医药与健康研究院 高亲和力的可溶性pdl-1分子
ES2946188T3 (es) 2016-11-09 2023-07-13 Univ Osaka Procedimiento para modificar una población de linfocitos T
EP3549957A4 (en) * 2016-11-30 2020-08-05 Sumitomo Dainippon Pharma Co., Ltd. AUXILIARY PEPTIDE WT1, AND COMBINATION OF DUDIT PEPTIDE AND CONJUGATE PEPTIDE ANTIGENIC FOR CANCER
WO2019131722A1 (ja) * 2017-12-27 2019-07-04 大日本住友製薬株式会社 Wt1由来ペプチドのコンジュゲート体およびこれを含む組成物
EP4036235A1 (en) * 2018-02-15 2022-08-03 National University Corporation Asahikawa Medical University Cancer antigen peptide
MX2021001938A (es) * 2018-08-22 2021-04-19 Fred Hutchinson Cancer Center Inmunoterapia dirigida a antigenos kras o her2.

Family Cites Families (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5726288A (en) 1989-11-13 1998-03-10 Massachusetts Institute Of Technology Localization and characterization of the Wilms' tumor gene
CN1560078B (zh) 1998-07-31 2011-06-22 株式会社国际癌症免疫研究所 基于癌抑制基因wt1的产物的癌抗原
ATE399179T1 (de) 1998-09-30 2008-07-15 Corixa Corp Zusammensetzungen und verfahren für wt1- spezifische immunotherapie
US7063854B1 (en) 1998-09-30 2006-06-20 Corixa Corporation Composition and methods for WTI specific immunotherapy
US20030235557A1 (en) 1998-09-30 2003-12-25 Corixa Corporation Compositions and methods for WT1 specific immunotherapy
CA2401070A1 (en) 2000-02-22 2001-08-30 Corixa Corporation Compositions and methods for diagnosis and therapy of malignant mesothelioma
ES2298353T3 (es) 2001-03-22 2008-05-16 International Institute Of Cancer Immunology, Inc. Peptido wt1 modificado.
GB0108491D0 (en) 2001-04-04 2001-05-23 Gendaq Ltd Engineering zinc fingers
CN1320923C (zh) 2001-06-29 2007-06-13 中外制药株式会社 含有基于癌抑制基因wt1的产物的癌抗原和阳离子脂质体的癌疫苗
US8735357B2 (en) 2001-09-28 2014-05-27 International Institute Of Cancer Immunology, Inc. Method of inducing antigen-specific T cells
US20050002951A1 (en) 2001-09-28 2005-01-06 Haruo Sugiyama Novel method of inducing antigen-specific t cells
WO2003106682A1 (ja) 2002-06-12 2003-12-24 中外製薬株式会社 Hla−a24拘束性癌抗原ペプチド
WO2004024175A1 (ja) 2002-09-12 2004-03-25 Haruo Sugiyama 癌抗原ペプチド製剤
ATE442378T1 (de) 2002-09-20 2009-09-15 Int Inst Cancer Immunology Inc Substituierte wt1-peptide
EP1584627B1 (en) 2003-01-15 2009-10-07 International Institute of Cancer Immunology, Inc. Dimerized peptide
KR101431312B1 (ko) 2003-06-27 2014-08-20 인터내셔널 인스티튜트 오브 캔서 이무놀로지 인코퍼레이티드 Wt1 백신 적응 환자의 선택 방법
CN101580538B (zh) 2003-11-05 2013-06-19 株式会社国际癌症免疫研究所 Wt1衍生的hla-dr-结合抗原肽
ES2556232T3 (es) 2004-03-31 2016-01-14 International Institute Of Cancer Immunology, Inc. Péptidos antigénicos del cáncer derivados de WT1
US7608769B2 (en) * 2004-05-12 2009-10-27 First Act, Inc. Packaged drum set
JP4719876B2 (ja) 2005-04-04 2011-07-06 国立大学法人愛媛大学 Hlaクラスii拘束性wt1抗原ペプチド
ES2542141T3 (es) 2005-10-17 2015-07-31 Sloan Kettering Institute For Cancer Research Péptidos WT1 de unión a HLA de clase II, y composiciones y métodos que los comprenden
ES2352855T3 (es) 2005-11-30 2011-02-23 International Institute Of Cancer Immunology, Inc. Nuevos compuestos peptídicos del tumor de wilms.
US7420880B2 (en) 2005-12-29 2008-09-02 Timex Group B.V. Multimode electronic device with calibrating/setting mechanism
ES2587980T3 (es) 2006-02-22 2016-10-28 International Institute Of Cancer Immunology, Inc Péptido WT1 con restricción HLA-A*3303 y composición farmacéutica que lo contiene
PL2010209T3 (pl) 2006-04-10 2017-04-28 Sloan Kettering Inst For Cancer Res Immunogeniczne peptydy WT-1 i sposoby ich użycia
CA2670658A1 (en) 2006-12-28 2008-07-10 International Institute Of Cancer Immunology, Inc. Hla-a*1101-restricted wt1 peptide and pharmaceutical composition comprising the same
MX2009009168A (es) 2007-02-27 2009-09-07 Int Inst Cancer Immunology Inc Metodo para activacion de celula t auxiliar y composicion para usarse en el metodo.
EP3173480A3 (en) 2007-03-05 2017-08-16 International Institute of Cancer Immunology, Inc. Cancer antigen-specific t-cell receptor gene, peptide encoded by the gene, and use of them
AR076349A1 (es) 2009-04-23 2011-06-01 Int Inst Cancer Immunology Inc Peptido auxiliar del antigeno del cancer
SG189287A1 (en) * 2010-10-05 2013-05-31 Int Inst Cancer Immunology Inc Method for activating helper t cell
WO2014098012A1 (ja) 2012-12-17 2014-06-26 大塚製薬株式会社 ヘルパーt細胞の活性化方法

Similar Documents

Publication Publication Date Title
JP2017006120A5 (https=)
FI3694529T3 (fi) Trispesifiset proteiinit ja niiden käyttömenetelmät
JP2017528117A5 (https=)
JP2019522461A5 (https=)
JP2019508013A5 (https=)
JP2017537611A5 (https=)
JP2018534950A5 (https=)
JP2017501130A5 (https=)
EA201590986A1 (ru) Антитела к ceacam5 и их применения
JP2015522576A5 (https=)
JP2015134796A5 (https=)
JP2017501129A5 (https=)
JP2016535009A5 (https=)
JP2016538344A5 (https=)
EP3533877A3 (de) Viraler vektor für den zielgerichteten gentransfer in gehirn und rückenmark
JP2012521768A5 (https=)
JP2016531927A5 (https=)
JP2010166916A5 (https=)
JPWO2019156137A5 (https=)
JP2015520178A5 (https=)
CY1117872T1 (el) Ολιγοπεπτιδικες ενωσεις και χρησεις εξ' aυτων
JP2012115277A5 (https=)
JP2012529293A5 (https=)
JP2019534884A5 (https=)
JP2012505657A5 (https=)